DB08875 and prostate cancer : inhibiting seed and disrupting soil ? Treatment with cabozantinib , an inhibitor of MET and P35968 signaling , has demonstrated clinical benefit in early trials in men with metastatic prostate cancer . Preclinical evidence suggests that cabozantinib can kill cancer cell seeds while disrupting angiogenesis and stromal cells in the metastatic soil .